When should G6PD (Glucose-6-Phosphate Dehydrogenase) deficiency be suspected clinically in patients, particularly those of African, Asian, or Mediterranean descent, presenting with symptoms of hemolytic anemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 24, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

When to Suspect G6PD Deficiency Clinically

Suspect G6PD deficiency in any patient of African, Asian, Mediterranean, or Middle-Eastern descent who presents with acute hemolysis (pallor, dark red/brown urine, and jaundice) occurring 24-72 hours after exposure to oxidative triggers such as infections, certain medications, or fava beans. 1, 2

High-Risk Populations Requiring Clinical Suspicion

  • Ethnic/Geographic ancestry: Mediterranean, African, Indian, or Southeast Asian descent 1, 3
  • Sex predilection: Males are predominantly affected (93.2% in one large cohort), though heterozygous females can be symptomatic 2, 4
  • Age of presentation: Most commonly presents between 1-3 years of age (mean age 22.8 months at first hemolytic crisis) 2

Classic Clinical Triad of Acute Hemolysis

The presentation typically occurs 24-72 hours (mean 36 hours) after oxidative stress exposure and includes: 2

  • Pallor (100% of cases) 2
  • Dark red/brown urine (89.6% of cases) - this is hemoglobinuria, not hematuria 5, 2
  • Jaundice (87.8% of cases) 3, 2

Specific Oxidative Triggers That Should Raise Suspicion

Dietary Triggers (Most Common - 83.4% of cases)

  • Fava beans (32.6%) - the most common precipitant 2
  • Falafel (19.4%), chickpeas (10.8%), broad beans (7.6%), green peas (4.4%), peanuts (3.8%), lentils (2.8%), black-eyed peas (2%) 2

Infectious Triggers (Second Most Common - 12.4% of cases)

  • Pneumonia (3.4%), tonsillitis (3.2%), typhoid fever (2.8%), hepatitis A (1.8%), urinary tract infections (1.2%) 2
  • Any acute infection can precipitate hemolysis 6, 4

Medication Triggers (4.2% of cases)

Absolutely contraindicated medications that should immediately raise suspicion: 1, 3

  • Dapsone (potent oxidant causing methemoglobinemia and hemolysis) 1
  • Methylene blue (methylthioninium chloride) - causes severe hemolytic anemia 1
  • Primaquine (contraindicated in severe deficiency) 1
  • Rasburicase 3

Common medications associated with hemolysis in clinical practice: 2

  • NSAIDs: Diclofenac sodium (2.4%), ibuprofen (0.8%) 3, 2
  • Aspirin (explicitly contraindicated) 3
  • Co-trimoxazole (0.4%), nitrofurantoin (0.2%) 2

Additional Clinical Scenarios Warranting Suspicion

Neonatal Presentation

  • Neonatal jaundice (likely due to impaired liver function rather than pure hemolysis) 6, 4
  • Elevated indirect bilirubin (>1.0 mg/dL when total bilirubin ≤5 mg/dL) suggests hemolysis 3

Chronic Presentation

  • Chronic non-spherocytic hemolytic anemia in the absence of acute stressors (rare, due to functionally severe variants) 6, 4

Variant-Specific Clinical Severity

Mediterranean variant (Gdmed): 1, 5

  • Found in Mediterranean regions, India, and Southeast Asia
  • Causes potentially life-threatening hemolysis - highest clinical suspicion warranted 1, 5

African variant (GdA-): 1, 5

  • Found in 10-15% of Black individuals
  • Causes milder, self-limited hemolysis 1, 5
  • Relatively resistant to severe primaquine-induced hemolysis 7

Laboratory Clues That Support Clinical Suspicion

  • Normocytic normochromic anemia with reticulocytosis 2
  • Heinz bodies on peripheral smear 2
  • Hemoglobinuria (dark urine without RBCs on microscopy) 5, 2

Common Pitfall to Avoid

Do not test during acute hemolytic crisis - G6PD levels can be falsely elevated during active hemolysis because young reticulocytes have higher enzyme activity. 3 Repeat testing after 3 months may be necessary for accurate diagnosis. 3

References

Guideline

Medications Contraindicated in G6PD Deficiency

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Study of Glucose-6-Phosphate Dehydrogenase Deficiency: 5 Years Retrospective Egyptian Study.

Endocrine, metabolic & immune disorders drug targets, 2018

Guideline

Management of G6PD Deficiency in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Diagnosis and management of G6PD deficiency.

American family physician, 2005

Guideline

Manejo de la Deficiencia de Glucosa-6-Fosfato Deshidrogenasa (G6PD)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.